This “Factor XI inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Factor XI inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Factor XI inhibitors Understanding
Current anticoagulants target enzymes, including FXa or thrombin, in the common pathway of coagulation, but the intrinsic pathway at the level of FXI and FXII has attracted attention in recent years. The intrinsic pathway is activated when blood comes into contact with medical devices like stents, mechanical heart valves, or central venous catheters, but evidence also suggests that it plays a role in clot stabilization and growth, he explained, noting additional evidence of attenuation of thrombosis in mice deficient in FXI or FXII and in animals with FXI or FXII inhibitors. The initiators of the intrinsic pathway are naturally occurring polyphosphates that can activate FXI and FXII, promote platelet activation, and lead to thrombosis. Factor XI has emerged as a promising target for new anticoagulants, and several strategies for inhibiting the enzyme to reduce stroke, thromboembolism, and bleeding risk are under investigation.
Factor XI inhibitors - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Factor XI inhibitors pipeline landscape is provided which includes the disease overview and Factor XI inhibitors treatment guidelines. The assessment part of the report embraces, in depth Factor XI inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Factor XI inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Factor XI inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Factor XI inhibitors Emerging Drugs
IONIS FXI LRX: Ionis Pharmaceuticals
Fesomersen, formerly known as IONIS-FXI-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway. IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI. In May 2015, Ionis entered into an exclusive license agreement with Bayer to develop and commercialize Ionis' programs targeting FXI for the treatment of clotting disorders. Under the agreement, Ionis has generated more than $185 million to date, including a $10 million milestone payment Ionis earned with Bayer's continuation decision. It is currently being evaluated in Phase II stage of development for the treatment of Thrombosis.
AB 023: Aronora, Inc.
AB023 (xisomab 3G3) is a recombinant factor XI (FXI) antibody that specifically inhibits contact activation of blood. AB023 is entirely unique in the growing armamentarium of FXI targeting drugs under development since it specifically inhibits FXI activation by factor XII (FXII) without inhibiting FXI feedback activation by thrombin. Since FXII deficiency in humans does not result in any known bleeding side-effects, as opposed to FXI deficiency (also known as hemophilia C), AB023 could be an exceptionally safe antithrombotic agent. As such, AB023 represents a fundamentally novel antithrombotic concept. AB023 is currently in the phase 2 clinical trial stage. It is being developed to prevent various thrombotic complications associated with chronic hemodialysis, as well as to limit blood clot formation on catheters and other intravascular, intracardiac or extracorporeal medical devices.
This segment of the report provides insights about the different Factor XI inhibitors drugs segregated based on following parameters that define the scope of the report.
There are approx. 8+ key companies which are developing the therapies for Factor XI inhibitors. The companies which have their Factor XI inhibitors drug candidates in the most advanced stage, i.e. phase II include Ionis Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Factor XI inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Factor XI inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor XI inhibitors drugs.
Geography Covered
- Global coverage
Factor XI inhibitors Understanding
Factor XI inhibitors: Overview
Current anticoagulants target enzymes, including FXa or thrombin, in the common pathway of coagulation, but the intrinsic pathway at the level of FXI and FXII has attracted attention in recent years. The intrinsic pathway is activated when blood comes into contact with medical devices like stents, mechanical heart valves, or central venous catheters, but evidence also suggests that it plays a role in clot stabilization and growth, he explained, noting additional evidence of attenuation of thrombosis in mice deficient in FXI or FXII and in animals with FXI or FXII inhibitors. The initiators of the intrinsic pathway are naturally occurring polyphosphates that can activate FXI and FXII, promote platelet activation, and lead to thrombosis. Factor XI has emerged as a promising target for new anticoagulants, and several strategies for inhibiting the enzyme to reduce stroke, thromboembolism, and bleeding risk are under investigation.
Factor XI inhibitors - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Factor XI inhibitors pipeline landscape is provided which includes the disease overview and Factor XI inhibitors treatment guidelines. The assessment part of the report embraces, in depth Factor XI inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Factor XI inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Factor XI inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Factor XI inhibitors.
Factor XI inhibitors Emerging Drugs Chapters
This segment of the Factor XI inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Factor XI inhibitors Emerging Drugs
IONIS FXI LRX: Ionis Pharmaceuticals
Fesomersen, formerly known as IONIS-FXI-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway. IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI. In May 2015, Ionis entered into an exclusive license agreement with Bayer to develop and commercialize Ionis' programs targeting FXI for the treatment of clotting disorders. Under the agreement, Ionis has generated more than $185 million to date, including a $10 million milestone payment Ionis earned with Bayer's continuation decision. It is currently being evaluated in Phase II stage of development for the treatment of Thrombosis.
AB 023: Aronora, Inc.
AB023 (xisomab 3G3) is a recombinant factor XI (FXI) antibody that specifically inhibits contact activation of blood. AB023 is entirely unique in the growing armamentarium of FXI targeting drugs under development since it specifically inhibits FXI activation by factor XII (FXII) without inhibiting FXI feedback activation by thrombin. Since FXII deficiency in humans does not result in any known bleeding side-effects, as opposed to FXI deficiency (also known as hemophilia C), AB023 could be an exceptionally safe antithrombotic agent. As such, AB023 represents a fundamentally novel antithrombotic concept. AB023 is currently in the phase 2 clinical trial stage. It is being developed to prevent various thrombotic complications associated with chronic hemodialysis, as well as to limit blood clot formation on catheters and other intravascular, intracardiac or extracorporeal medical devices.
Factor XI inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Factor XI inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players in Factor XI inhibitors
There are approx. 8+ key companies which are developing the therapies for Factor XI inhibitors. The companies which have their Factor XI inhibitors drug candidates in the most advanced stage, i.e. phase II include Ionis Pharmaceuticals.
Phases
This report covers around 8+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Factor XI inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Factor XI inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Factor XI inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor XI inhibitors drugs.
Factor XI inhibitors Report Insights
- Factor XI inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Factor XI inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Factor XI inhibitors drugs?
- How many Factor XI inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Factor XI inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Factor XI inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Factor XI inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Factor XI inhibitors: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
- Comparative Analysis
IONIS FXI LRX: Ionis Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
SHR-2285: Jiangsu Hengrui Medicine
- Product Description
- Research and Development
- Product Development Activities
Preclinical Stage Products
- Comparative Analysis
A 336: Klus Pharma
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Factor XI inhibitors Key Companies
Factor XI inhibitors Key Products
Factor XI inhibitors- Unmet Needs
Factor XI inhibitors- Market Drivers and Barriers
Factor XI inhibitors- Future Perspectives and Conclusion
Factor XI inhibitors Analyst Views
Factor XI inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for Factor XI inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Factor XI inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Ionis Pharmaceuticals
- eXIthera
- Anthos Therapeutics
- Bayer HealthCare
- Klus Pharma
- Aronora therapeutics
- Bristol-Myers Squibb/Janssen Pharmaceuticals
- Jiangsu Hengrui Medicine
